43 results on '"Gronemeyer, Hinrich"'
Search Results
2. Data from Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
3. Supplementary Figure 1 from Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008
4. Data from Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008
5. Supplementary Figure 4 from Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008
6. Supplementary Figure 3 from Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
7. Supplementary Figure 5 from Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
8. Supplementary Figure 1A-D from Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
9. Supplementary Figure 2 from Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008
10. Supplementary Table 1, Figure Legends 1-5 from Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
11. Supplementary Figure 4 from Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008
12. Supplementary Methods from Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008
13. Supplementary Figure 5 from Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008
14. Supplementary Table 1 from Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008
15. Supplementary Figure 1 from Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008
16. Supplementary Figure 3 from Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
17. Supplementary Figure 5 from Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008
18. Supplementary Figure 2 from Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
19. Data from Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008
20. Supplementary Figure 2 from Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008
21. Supplementary Figure 5 from Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
22. Supplementary Figure 3 from Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008
23. Supplementary Figure 1A-D from Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
24. Supplementary Figure 2 from Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
25. Supplementary Table 4 from Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
26. Supplementary Methods from Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008
27. Data from Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
28. Supplementary Figure 3 from Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008
29. Supplementary Table 1, Figure Legends 1-5 from Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
30. Supplementary Figure 1E-J from Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
31. Supplementary Table 4 from Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
32. Supplementary Figure 1E-J from Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
33. Supplementary Figure 4 from Multivalent DR5 Peptides Activate the TRAIL Death Pathway and Exert Tumoricidal Activity
34. Data from Multivalent DR5 Peptides Activate the TRAIL Death Pathway and Exert Tumoricidal Activity
35. Supplementary Figure 2 from Multivalent DR5 Peptides Activate the TRAIL Death Pathway and Exert Tumoricidal Activity
36. Data from Multivalent DR5 Peptides Activate the TRAIL Death Pathway and Exert Tumoricidal Activity
37. Supplementary Figure 5 from Multivalent DR5 Peptides Activate the TRAIL Death Pathway and Exert Tumoricidal Activity
38. Supplementary Figure 1 from Multivalent DR5 Peptides Activate the TRAIL Death Pathway and Exert Tumoricidal Activity
39. Supplementary Figure Legends 1-5 from Multivalent DR5 Peptides Activate the TRAIL Death Pathway and Exert Tumoricidal Activity
40. Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008
41. Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
42. Multivalent DR5 Peptides Activate the TRAIL Death Pathway and Exert Tumoricidal Activity
43. Rexinoid-Triggered Differentiation and Tumor-Selective Apoptosis of Acute Myeloid Leukemia by Protein Kinase A–Mediated Desubordination of Retinoid X Receptor
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.